

Enhancing active ingredient biosynthesis in Chinese herbal medicine: biotechnological strategies and molecular mechanisms

Ziyi Guo¹, Ning Yang² and Delin Xu^{1,2}

¹ Department of Cell Biology, Zunyi Medical University, Zunyi, Guizhou, China

² Department of Medical Instrumental Analysis, Zunyi Medical University, Zunyi, Guizhou, China

ABSTRACT

Background: Chinese herbal medicine (CHM) is a fundamental component of traditional Chinese medical practice, offering a rich source of natural remedies with significant therapeutic potential. However, the scarcity of active ingredients and complex extraction procedures present substantial challenges to their widespread clinical application. This review aims to address this gap by exploring the potential of modern biotechnological advancements in enhancing the biosynthesis of these valuable compounds.

Methodology: The study takes a comprehensive approach, delving into the chemical composition of CHM's active ingredients and elucidating their biosynthetic pathways and molecular regulatory mechanisms. Additionally, it surveys recent progress in extraction methodologies and evaluates engineering strategies aimed at synthetic production. This multifaceted analysis forms the foundation for examining the role of synthetic biology in augmenting CHM's active ingredient synthesis.

Results: Our examination provides insights into the intricate biosynthetic pathways governing the formation of CHM's active ingredients, as well as the complex molecular regulatory networks that underlie these processes. Furthermore, the review highlights advancements in extraction techniques, demonstrating their ability to streamline and enhance the isolation of these compounds. Engineering approaches for synthetic production, including metabolic engineering and synthetic biology tools, are assessed for their potential to overcome natural limitations and scale up production.

Conclusions: By integrating insights from biosynthesis, molecular regulation, extraction methodologies, and synthetic biology, this review establishes a robust theoretical framework for enhancing the production of CHM's active ingredients. The proposed strategies and practical guidance aim to facilitate their broader utilization in modern medicine while promoting sustainability and accessibility within this invaluable medicinal heritage.

Submitted 27 August 2024

Accepted 7 January 2025

Published 10 February 2025

Corresponding authors

Ning Yang, 15077823203@163.com
Delin Xu, xudelin2000@163.com

Academic editor

Zothanpuia

Additional Information and
Declarations can be found on
page 17

DOI 10.7717/peerj.18914

© Copyright

2025 Guo et al.

Distributed under

Creative Commons CC-BY 4.0

OPEN ACCESS

Subjects Biochemistry, Plant Science, Metabolic Sciences

Keywords Chinese herbal medicine (CHM), Active ingredients, Molecular regulation, Metabolic engineering, Biosynthesis

INTRODUCTION

Chinese herbal medicine (CHM) is a cornerstone of traditional Chinese medicine, with a rich history of clinical use and a vast repository of natural medicinal resources. CHM contains a wide array of active ingredients, including alkaloids, volatile oils, and flavonoidss ([Shi et al., 2021](#)), which have demonstrated significant therapeutic potentialt ([Delfin, Watanabe & Tohge, 2019](#)). Prominent examples include artemisinin and paclitaxel, which have made major contributions to drug development ([Guo et al., 2023](#)). However, the limited availability and complex extraction processes of these active ingredients hinder their widespread utilization in modern medicine ([Hu et al., 2023](#)).

Recent advances in biotechnology offer new opportunities for enhancing the synthesis of active ingredients in CHM. A comprehensive understanding of their structural characteristics, biosynthetic pathways, and molecular regulatory mechanisms is essential for efficient and artificial synthesis ([Ma et al., 2020](#)). Elucidating the chemical structure of an active ingredient enables the exploration of its biosynthetic pathway and molecular regulation, providing a theoretical foundation for biotechnological applications ([Xu et al., 2021a](#)). Research on biosynthetic pathways reveals the formation processes of active ingredients within plants, while the analysis of molecular regulatory mechanisms offers innovative strategies for precise regulation of biosynthesis ([Li & Wu, 2018](#); [Sun et al., 2023](#)).

This review provides a comprehensive overview of the types, biosynthetic pathways, and molecular regulatory mechanisms of active components in CHM. It discusses engineering design strategies for the synthetic production of these active ingredients and explores the potential applications and limitations of relevant technologies in the conservation of medicinal plant resources and large-scale production of active ingredients ([Li & Chen, 2024](#)). Through this analysis and discussion, this paper aims to provide a theoretical foundation and practical guidance for the efficient synthesis of active ingredients in CHM, thereby facilitating their broader application and development in modern medicine.

Intended audience

This literature review is intended for researchers, academics, and professionals in plant biology, biotechnology, pharmacognosy, pharmacology, and traditional Chinese medicine (TCM). It provides a comprehensive overview of current advances in the biosynthesis pathways of secondary metabolites in medicinal plants, highlighting key enzymes, regulatory mechanisms, and genetic engineering strategies. Additionally, the review addresses regulatory challenges and ethical implications related to the biotechnological production of herbal medicines, making it valuable for regulatory bodies, policymakers, and interdisciplinary scholars. By consolidating recent studies and identifying research gaps, this manuscript serves as a comprehensive resource for stakeholders aiming to advance the integration of modern biotechnology with traditional medicinal practices and to inform ongoing and future research endeavors.

SURVEY METHODOLOGY

In accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines, a total of 214 articles were identified from PubMed (156), Google Scholar (31), and Scopus (27), and 37 articles were retrieved from other sources. After successive filtrations to eliminate irrelevant and duplicate studies (134), 117 highly relevant cutting-edge literatures were identified. Consequently, a systematic review and meta-analysis was conducted, incorporating 117 articles, which were analyzed and evaluated in depth to identify studies that promote the biosynthesis of the active ingredients of Chinese herbal medicines (Fig. 1).

Types and biosynthetic pathways of ingredients in CHM

CHM encompasses a diverse array of bioactive compounds ([Cheng, 2021](#)), primarily classified into alkaloids, saponins, flavonoids, polysaccharides, terpenoids, volatile oils, phenols, and organic acids ([Lu & Jiang, 2013](#); [Daley & Cordell, 2021](#); [Wu et al., 2022](#); [Islam et al., 2023](#)). These compounds exhibit a spectrum of pharmacological activities, including antibacterial, anti-inflammatory, antioxidant, anti-tumor, immune-regulating, and cardiovascular protective effects ([Chiş et al., 2023](#); [Liu et al., 2017](#); [Narayananakutty, Famurewa & Oprea, 2024](#); [Zhang et al., 2023a](#); [Zhou et al., 2016](#)). The synergistic interactions among these compounds contribute to the holistic therapeutic effects of CHM ([Zhao et al., 2023a](#)).

The biosynthesis of secondary metabolites in plants involves complex metabolic pathways, including the acetate-malonic acid pathway, shikimic acid pathway, amino acid pathway, isoprene-like pathway, and polyamine biosynthesis pathway ([Dawson et al., 2022](#); [Javan et al., 2024](#); [Rhee, Kim & Lee, 2007](#)). These pathways utilize primary metabolites to synthesize a wide variety of complex secondary metabolites, underscoring the biochemical versatility that underpins the pharmacological diversity of CHM ([Kishimoto et al., 2016](#); [Zhang et al., 2023b](#)).

Biosynthetic pathway of alkaloids

Alkaloids represent a significant class of active ingredients in CHM, renowned for their diverse pharmacological properties, including analgesic, antimicrobial, and anticancer activities. The biosynthesis of alkaloids is a highly studied area, with several key pathways elucidated and even reconstructed in heterologous hosts to enhance production scalability and sustainability ([Zhou et al., 2023](#)). For instance, tropane alkaloids such as cocaine; benzylisoquinoline alkaloids like berberine and sanguinarine; monoterpenoid indole alkaloids including brucine, strychnine, and iboga; and steroidal alkaloids such as alpha-tomatine exemplify the structural and functional diversity within this group ([Jain, Tripathi & Tripathi, 2023](#); [Lu et al., 2024](#); [Wei et al., 2024](#)). Despite significant advancements, the biosynthetic pathways of certain alkaloids, including diterpenoid alkaloids like aconitine, pyrrole alkaloids, and aristolochic acid—a benzylisoquinoline alkaloid—remain to be fully characterized.

Recent case studies have demonstrated the potential of biotechnological approaches in enhancing alkaloid production through meticulous gene identification, pathway assembly,




Figure 1 PRISMA flow diagram.

Full-size DOI: 10.7717/peerj.18914/fig-1

and optimization. For example, the successful reconstruction of scopolamine, leonurine, and morphine biosynthetic pathways in heterologous hosts highlights the feasibility of using genetic engineering to achieve higher yields and sustainable production of these valuable compounds (Wicks, Hudlicky & Rinner, 2021) (Fig. 2). These advancements not only facilitate large-scale production but also pave the way for the discovery and utilization of novel alkaloids with therapeutic potential.

Biosynthetic pathways of flavonoids

Flavonoids are synthesized through the phenylpropanoid pathway, which begins with the amino acid phenylalanine (Fig. 3). This precursor undergoes a series of enzymatic transformations, starting with the conversion of phenylalanine to cinnamic acid catalyzed by phenylalanine ammonia-lyase (PAL). Subsequently, cinnamic acid is hydroxylated to coumaric acid by cinnamate 4-hydroxylase (C4H), which is then transformed into chalcone by chalcone synthase (CHS) (Chen et al., 2019). Chalcone isomerase (CHI) catalyzes the isomerization of chalcone to naringenin, a pivotal intermediate that serves as a precursor for various flavonoid subclasses, including flavones, flavonols, flavanols, flavanones, and anthocyanins. This biosynthetic route not only underscores the structural diversity of flavonoids but also their significance in contributing to the pharmacological efficacy of CHM through their antioxidant and anti-inflammatory properties.

Biosynthetic pathways of terpenoids

Terpenoids are another major class of bioactive compounds in CHM, synthesized via two primary pathways: the mevalonate (MVA) pathway and the methylerythritol phosphate




Figure 2 Biosynthetic pathway of three alkaloids.

Full-size DOI: 10.7717/peerj.18914/fig-2




Figure 3 Biosynthetic pathways of flavonoids.

Full-size DOI: 10.7717/peerj.18914/fig-3

(MEP) pathway (Xu et al., 2021b) (Fig. 4). Both pathways generate the essential five-carbon (C_5) building blocks isopentenyl pyrophosphate (IPP) and dimethylallyl pyrophosphate (DMAPP) (Gao et al., 2021; Upadhyay et al., 2018). These intermediates undergo condensation reactions to form larger prenyl diphosphates such as farnesyl pyrophosphate (FPP), geranyl diphosphate (GPP), and geranylgeranyl diphosphate (GGPP). These compounds are then subjected to cyclization and various enzymatic modifications, leading to the vast structural diversity of terpenoids (Chang, Li & Huang, 2018; Kuang et al., 2016; Wang et al., 2017). The intricate biosynthetic pathways of terpenoids not only contribute to the rich pharmacological profile of CHM but also offer numerous targets for metabolic engineering aimed at enhancing the production of specific terpenoid compounds with therapeutic benefits.




Figure 4 Biosynthetic pathways of terpenoids.

Full-size DOI: 10.7717/peerj.18914/fig-4

Molecular regulatory mechanism for the synthesis of pharmaceutical ingredients

The synthesis of pharmaceutical active ingredients is regulated by a complex interplay of molecular mechanisms, including signal transduction, enzyme catalysis, and gene expression regulation ([Perez-Matas et al., 2024](#); [Zheng et al., 2023](#)).

Enzymes involved in biosynthesis of secondary metabolites

The biosynthesis of alkaloids, flavonoids, and terpenoids involves multiple enzyme-catalyzed steps. The activity, expression, and localization of these enzymes are tightly regulated ([Zhou et al., 2021](#)), influencing the production of secondary metabolites.

Key enzymes involved in alkaloid biosynthesis include scopolamine hydroxylase, putrescine N-methyltransferase, and N-methyl-putrescine oxidase ([Qu, Safanova & De Luca, 2019](#)). The discovery of these enzymes has provided insights into the regulation of alkaloid production ([Jiang et al., 2024a](#)).

Key enzymes in the flavonoid synthesis pathway include PAL, C4H, 4CL, and CHI ([Li et al., 2018](#); [Unuofin & Lebelo, 2020](#)). CHS is a rate-limiting enzyme that catalyzes the production of naringenin chalcone, the precursor for downstream flavonoid synthesis ([Zhong et al., 2022](#)). CHI accelerates the isomerization of naringenin chalcone to naringenin, increasing the efficiency of the reaction ([Lin, Chen & Dai, 2022](#)).

Terpene synthases (TPS) catalyze the formation of diverse scaffolds from direct precursors (Li *et al.*, 2023a). These scaffolds are then modified by dehydrogenases, reductases, glycosyltransferases, acyltransferases, and methyltransferases, resulting in the production of a wide variety of terpenoids with varying structures and biological activities (Jiang *et al.*, 2024b; Li *et al.*, 2023b; Yang & Drugs, 2017; Yang *et al.*, 2023a).

Genes involved in the biosynthesis of pharmaceutical active ingredients

Gene expression plays a critical role in regulating the synthesis of bioactive drug ingredients. By controlling the expression of specific genes, intracellular metabolic pathways can be manipulated (Zhu, Yuan & Liu, 2024), thereby influencing the production of target molecules.

The genes involved in biosynthesis often belong to plant gene families, such as the cytochrome P450 (P450) family (Lv, Liu & He, 2017). Identifying specific genes within these families can be challenging due to gene expansion and contraction during evolution (Yang, Mao & Li, 2005). However, recent studies have revealed that genes involved in secondary metabolite biosynthesis tend to cluster together in the plant genome, forming metabolic gene clusters (Table 1) (Chen *et al.*, 2023; Liao *et al.*, 2022; Zuo *et al.*, 2023). This gene clustering allows researchers to predict the biosynthesis pathways of secondary metabolites directly from genomic information. For example, the poppy genome contains a gene cluster for noscapine biosynthesis, which includes genes encoding O-methyltransferase and P450s (Miao *et al.*, 2023; Rashid *et al.*, 2023; Zhang *et al.*, 2024a).

In addition to plant genes, it is increasingly recognized that many pharmaceutically relevant compounds traditionally isolated from plant materials are actually synthesized by symbiotic or endophytic fungi residing within the plant tissues (Schafhauser *et al.*, 2019). These endophytic fungi possess their own biosynthetic pathways, enabling the production of complex bioactive metabolites such as paclitaxel, vincristine, and camptothecin (Birat *et al.*, 2022; Subban & Kempken, 2023; Doan *et al.*, 2024). This symbiotic relationship enhances the biosynthetic capabilities of both host plants and fungi, providing a sustainable and scalable source for valuable pharmaceutical compounds. Recent advancements in genomics and metabolomics have facilitated the identification of novel bioactive compounds produced by these microorganisms, expanding the repertoire of pharmacologically important substances and offering new avenues for biotechnological applications (Venugopalan & Srivastava, 2015; Hridoy *et al.*, 2022; Tiwari & Bae, 2022).

Furthermore, transcription factors play a key role in regulating the biosynthesis of active medicinal ingredients. They modulate gene transcription rates and can be activated by various stimuli (Khoso *et al.*, 2024; Zhao *et al.*, 2023b). For instance, in the biosynthesis of artemisinin, a crucial antimalarial compound, transcriptional regulatory networks reveal intricate interactions that govern its production. Similarly, in *Taxus chinensis*, the MYB transcription factor TcMYB29a activates the expression of taxadiene-5 α -hydroxylase (T5OH), enhancing taxol production (Gao, 2015; Liang *et al.*, 2020). Salicylic acid (SA) can also boost paclitaxel yield by regulating specific transcription factors. In *Salvia miltiorrhiza*, the WRKY transcription factor SmWRKY2 activates SmCPS1 expression and promotes tanshinone production (Goyal *et al.*, 2023; Javed & Gao, 2023; Kundu &

Table 1 Plant gene clusters and related genomes reported so far.

| Time/ year | Plant gene clusters | Related genomes |
|---------------|--|---|
| 1997 | DIMBOA gene cluster | |
| 2000 | | The genome of <i>Arabidopsis thaliana</i> |
| 2002 | | The genome of <i>Oryza sativa</i> |
| 2004 | Momilactones and avenacins gene cluster | |
| 2008 | Thalianol gene cluster | The genome of <i>Lotus japonicus</i> |
| 2009 | Phytocassanes and oryzalides gene cluster | The genome of <i>Zea mays</i> , <i>Cucumis sativus</i> and <i>Sorghum bicolor</i> |
| 2010 | | The genome of <i>Ricinus communis</i> |
| 2011 | Linamarin, marneral, dhurrin and s lignin gene cluster | The genome of <i>Selaginella moellendorffii</i> |
| 2012 | Noscapine gene cluster | The genome of <i>Solanum lycopersicum</i> The genome of <i>Manihot esculenta</i> The genome of <i>Citrullus lanatus</i> The genome of <i>Hordeum vulgare</i> |
| 2013 | 20-Hydroxybetulinic acid, arabidiol, α -tomatine, α -chaconine and α -solanine gene cluster | |
| 2014 | Casbene and cucurbitacins gene cluster | The genome of <i>Brassica napus</i> |
| 2015 | Tirucalla-7,24-dien- β -ol and baruol gene cluster | |
| 2016 | β -Diketones and FPT gene cluster | |
| 2018 | | The genome of <i>Papaver somniferum</i> |
| 2020 | Acylsugar, falcarindiol, 5,10-diketo-casbene and Zx gene cluster | The genome of <i>Solanum tuberosum</i> |
| 2021 | Hydroxycinnamoyl-tyramine and hydroxycinnamoyl-putrescine gene cluster | The genome of <i>Ginkgo biloba</i> |
| 2022 | | The genome of <i>Alsophila spinulosa</i> |
| 2023 | | The genome of <i>Lonicera macranthoides</i> |
| 2024 | UGT3 gene cluster | The genome of <i>Fagopyrum esculentum Moench</i> |

Vadassery, 2021; Mahiwal, Pahuja & Pandey, 2024; Wani et al., 2021). Therefore, understanding the role of transcription factors in biosynthesis provides opportunities to manipulate gene expression and improve the production of pharmaceutical active ingredients (*LaFountain & Yuan, 2021; Ren et al., 2023; Wang, Wu & Wei, 2024*).

Effects of non-coding RNA on synthesis of pharmaceutical active ingredients
 Additionally, non-coding RNA (ncRNA) plays a role in regulating the synthesis of pharmaceutical active ingredients (*Zhan & Meyers, 2023*). It affects the post-transcriptional regulatory system of plants, influencing the secretion and accumulation of secondary metabolites. Specifically, microRNAs (miRNAs) and small interfering RNAs (siRNAs) are the most common ncRNAs in plants (*Li et al., 2024a*). MiRNAs and siRNAs can identify target genes and degrade their messenger RNA, modulating gene expression. They are involved in the regulation of plant secondary metabolite biosynthesis. For example, miRNAs can enhance flavonoid biosynthesis by regulating MYB factor expression in plants (*Hu et al., 2021*).

In summary, the molecular regulatory mechanisms involved in the synthesis of pharmaceutical active ingredients are complex, encompassing enzyme catalysis, gene expression, regulation by transcription factors, and signal transduction. An in-depth analysis of the synthesis mechanisms of several key components within this system not only uncovers the intricacies of natural regulation but also paves the way for innovative approaches to optimize drug development strategies and enhance agricultural production efficiency, demonstrating unprecedented scientific value and application potential (Fig. 5).

Engineering design of biosynthetic pharmaceutical ingredients

The artificial biosynthesis of pharmaceutical active ingredients is a comprehensive, interdisciplinary field encompassing biochemistry, molecular biology, chemical engineering, and other related disciplines (Ji *et al.*, 2024; Zhang *et al.*, 2014; Zhou *et al.*, 2022). By selecting and expressing specific enzymes, providing precursor substances, regulating metabolic pathways, and optimizing reaction conditions, continuous improvement in synthesis strategies and key technical aspects (Chen *et al.*, 2020; Deng *et al.*, 2020; Huang *et al.*, 2021) are expected to achieve efficient and customized production of target pharmaceutical active ingredients (Ding *et al.*, 2023). This approach provides theoretical and technical support for transitioning from traditional reliance on natural resources to efficient, environmentally friendly, and sustainable industrial production modes for Chinese medicine active ingredients.

Main points of engineering design

Metabolic engineering and synthetic biology offer new approaches for producing pharmaceutical active ingredients. However, the complex biosynthetic pathways and low efficiency of heterologous synthesis remain challenges (Zhong *et al.*, 2020). To address these challenges, it is essential to: (1) Mine and analyze biosynthetic genes for active components of traditional Chinese medicine. (2) Elucidate their biosynthetic pathways. (3) Optimize heterologous synthesis.

Novel chassis cells, such as *Lipomyces starkeyi* (Jin *et al.*, 2023) and *Methylobacterium extorquens* (Yang *et al.*, 2023b), combined with gene editing tools, can create efficient production systems for complex active ingredients. For example, researchers have developed a Pichia strain with high tyrosine productivity to synthesize tyrosine-derived compounds (Liu *et al.*, 2023; Lu, 2021; Xia *et al.*, 2023; Zhou *et al.*, 2024).

Advancements in gene editing technologies, such as CRISPR-Cas, have enabled precise genetic modifications of chassis cells (Li & Xia, 2020). This technology allows for targeted gene insertion and deletion, regulation of gene expression, optimization of metabolic pathways.

Heterologous synthesis of pharmaceutical active ingredients

Heterologous synthesis entails the production of pharmaceutical active ingredients in host organisms that do not naturally synthesize these compounds. This biotechnological strategy provides precise control over the production process (Guo *et al.*, 2022), mitigates environmental factors influencing natural biosynthesis (Du *et al.*, 2024), and facilitates the




Figure 5 The molecular regulatory mechanism of the synthesis of several crucial pharmaceutical active ingredients.
Full-size DOI: 10.7717/peerj.18914/fig-5

generation of rare or geographically restricted compounds ([Liu et al., 2019a](#); [Yuan et al., 2024](#)).

Advancements in metabolic engineering, gene editing, and synthetic biology have transformed the landscape of active pharmaceutical ingredient production, particularly for those derived from traditional Chinese medicine (TCM). By engineering hosts such as *Escherichia coli* and *Saccharomyces cerevisiae*, researchers have successfully replicated and optimized natural biosynthetic pathways to achieve higher yields and enhanced efficiency ([He et al., 2024](#); [Li et al., 2024b](#)). A prominent example is the engineered yeast's capacity to produce artemisinin, which significantly lowers costs while increasing availability compared to conventional plant extraction methods ([Paddon et al., 2013](#)).

From an economic perspective, heterologous synthesis diminishes reliance on variable agricultural outputs and alleviates risks associated with natural resource depletion. The scalability inherent in microbial fermentation guarantees a consistent and reliable supply of high-value pharmaceuticals, thereby addressing global healthcare demands ([Zhang et al., 2024b](#)). Clinically, manufacturing pharmaceuticals within controlled environments enhances compound quality and purity by minimizing contaminants, thus ensuring greater patient safety ([Ye et al., 2024](#)).

Successful applications include the genetic modification of *E. coli* for resveratrol production aimed at cardiovascular health benefits, as well as berberine biosynthesis in *S. cerevisiae*—an alkaloid recognized for its antimicrobial and anti-inflammatory properties ([Han & Li, 2023](#); [Liu et al., 2024](#)). These case studies illustrate both the versatility and practical significance of heterologous synthesis in developing innovative therapies rooted in traditional medicinal practices.

In conclusion, heterologous synthesis plays a crucial role in contemporary biotechnology for producing pharmaceutical active ingredients. Its capability to enhance production efficiency, ensure sustainability, and support the development of high-quality medicinal compounds renders it indispensable for advancing both traditional healing practices and modern healthcare solutions.

Joint strategies of synthetic biology and metabolic engineering

The convergence of synthetic biology and metabolic engineering has revolutionized modern medicine by addressing challenges inherent in traditional drug production. These technologies enable cost-effective and resource-efficient production while promoting innovation in manufacturing processes to achieve environmentally sustainable, economical, and efficient outcomes, which promise to be applied in the production of Chinese herbal active ingredients ([Qiu et al., 2024](#)).

For plant alkaloids, the biosynthesis and identification of regulatory elements have advanced the molecular breeding of medicinal plants, facilitating the heterologous production of medicinal alkaloids ([Zhao et al., 2020](#)). Genome analysis provides insights into the evolutionary processes governing alkaloid biosynthesis genes, informing the selection of appropriate pathways for synthesizing targeted alkaloids within plants. This considers the complexity and distribution of metabolic networks and the challenges of establishing genetic transformation systems.

For flavonoids, recent studies have established the therapeutic potential of flavonoids derived from fruits, vegetables, and medicinal plants (Ding *et al.*, 2023). However, traditional production methods, such as plant extraction and chemical synthesis, face scalability limitations for mass industrial production. Advanced genetic engineering tools enable the modification of biosynthetic pathways in plants, microorganisms, and industrially significant entities, expanding opportunities for large-scale flavonoid production (Huang *et al.*, 2023). Co-culture engineering approaches leverage the capabilities of multiple engineered microbial strains to reconstruct targeted biosynthetic pathways, overcoming the constraints of traditional monocultures.

For terpenoids, metabolic engineering has been extensively explored in cyanobacteria, bacteria, and yeast. Englund *et al.* (2018) demonstrated the potential of cyanobacteria as a robust chassis for synthetic biology, achieving high isoprene yields through overexpression of genes in the MEP pathway and evaluating the influence of metabolic pathways such as the Calvin cycle and glycolysis on terpenoid synthesis (Englund *et al.*, 2018; Sahu *et al.*, 2023).

Plant metabolic engineering for detoxification of plant toxins involves transferring regulatory mechanisms governing plant secondary metabolite synthesis into heterologous systems for precise control. Synthetic biology strategies precisely modulate the localization of secondary metabolites to enhance plant growth and stress responses. Researchers have successfully rewired plant hormone pathways to manipulate plant development and structure (Chao *et al.*, 2019). Additionally, plant-microbe interactions mediated through metabolites present opportunities for engineering efforts aimed at improving plant growth and resilience.

Discussion and prospect

Despite significant advancements in understanding the biosynthetic pathways and regulatory mechanisms of active ingredients in CHM, considerable gaps persist in CHM active ingredient research. Current progress underscores the necessity for intensified exploration of biosynthetic pathways, refinement of metabolic control, accelerated research through novel technologies, and the development of innovative production strategies. This forward-looking roadmap holds substantial promise for unlocking CHM's full potential in health promotion and sustainable development.

In-depth understanding of biogenic synthesis pathways and regulatory mechanisms

A comprehensive understanding of the biosynthetic pathways and regulatory mechanisms of active ingredients in CHM is crucial for enhancing their yield and quality. Systems biology approaches, including genomics, transcriptomics, and metabolomics, have provided detailed maps of these pathways, identifying key enzymes and regulatory factors (Ma *et al.*, 2015). For instance, genomics has facilitated the identification of gene clusters responsible for secondary metabolite production, while transcriptomics has elucidated gene expression patterns under various environmental conditions. Metabolomics

complements these studies by profiling the metabolites involved in these pathways, offering insights into the dynamic changes during synthesis.

However, these methodologies are not without limitations. Genomic studies often face challenges related to the complexity of plant genomes and the presence of gene families with redundant functions. Transcriptomic analyses can be confounded by the spatial and temporal variability of gene expression, making it difficult to pinpoint specific regulatory mechanisms. Metabolomics, while powerful, may miss low-abundance metabolites or those that are rapidly metabolized. Additionally, epigenetic regulation studies, which explore DNA methylation, histone modification, and non-coding RNA impacts, provide valuable information but are still in the nascent stages concerning CHM.

Research on microbial-plant interactions, particularly the role of rhizosphere microbiota and endophytes in biosynthetic synthesis, offers another layer of complexity. While these interactions can enhance the production of certain metabolites, they also introduce variability that complicates the reproducibility of CHM preparations. Understanding the spatio-temporal regulation mechanisms of intercellular metabolic flow remains a significant challenge, as environmental factors and developmental stages intricately influence biosynthetic processes.

Precise regulation of secondary metabolic pathways

With a foundational understanding of biosynthetic pathways and regulatory mechanisms, precise regulation of secondary metabolic pathways can be achieved to enhance the yield and quality of active ingredients. Metabolic engineering techniques, such as the overexpression of key enzymes or regulatory factors and the knockout of inhibitory elements (*Liu et al., 2019b*), have shown promise in boosting biosynthetic production. Synthetic biology approaches further enable the design of artificial biosynthetic pathways by introducing heterologous genes or optimizing enzyme activity, thereby tailoring the production of specific metabolites. Monocellular technology provides a more refined approach by allowing the investigation of cell or tissue-specific secondary metabolic pathways and product accumulation mechanisms. This precision facilitates targeted pathway regulation, optimizing CHM production to meet increasing market demands.

However, these strategies also present challenges. Metabolic engineering often requires extensive trial and error to identify optimal gene combinations, and synthetic biology approaches may encounter issues related to the stability and scalability of engineered pathways. Additionally, monocellular technologies need to balance precision with the inherent biological variability of living systems, which can affect the consistency of metabolite production.

Use of new technologies to accelerate the research process

Novel technologies offer powerful tools for studying the biosynthetic pathways and regulatory mechanisms of active ingredients in CHM. High-throughput sequencing technologies, such as RNA-Seq and advanced metabolomics platforms, enable rapid and comprehensive analysis of gene expression and metabolite profiles. Microscopic techniques, including confocal and electron microscopy, allow for the visualization of

organelle and molecular interactions within biosynthetic pathways ([Yuan et al., 2023](#)). Furthermore, artificial intelligence (AI) and machine learning (ML) techniques facilitate the analysis of large datasets, identifying patterns and predicting key factors in biosynthesis pathways.

While these technologies significantly accelerate research, they also introduce new challenges. The sheer volume of data generated by high-throughput methods requires robust computational infrastructure and sophisticated data analysis algorithms to extract meaningful insights. AI and ML models, although powerful, depend heavily on the quality and quantity of input data and may produce biased or inaccurate predictions if not properly validated. Additionally, advanced microscopic techniques necessitate specialized expertise and equipment, potentially limiting their accessibility for some research groups.

Explore new ways of production

The biosynthesis of active ingredients in CHM has catalyzed new avenues for drug development. A deeper understanding of biosynthetic pathways and regulatory mechanisms enables the design and synthesis of new analogues with improved biological activity, reduced toxicity, and enhanced stability. Synthetic biology facilitates the construction of complex CHM active ingredients that are otherwise inaccessible through traditional extraction methods. Moreover, regulating biosynthetic pathways can identify novel therapeutic targets, contributing to innovative therapies for diseases such as metabolic disorders and cancer. For example, targeting glutaminase (GLS), a key enzyme in glutamine metabolism, has been shown to inhibit tumor growth and enhance immunotherapy effectiveness in certain cancers ([Li, Ng & Ng, 2023](#)).

However, these biotechnological advancements are not without inherent limitations and risks. The introduction of genetically modified organisms (GMOs) for the production of CHM compounds raises ecological and ethical concerns, including potential unintended impacts on ecosystems and biodiversity. Additionally, the synthesis of novel analogues may result in unforeseen pharmacological effects, necessitating extensive safety evaluations. Regulatory frameworks must evolve to address these challenges, ensuring that biotechnological innovations in CHM are both safe and sustainable.

Critical evaluation of methodologies and future directions

While the integration of synthetic biology and metabolic engineering holds immense potential for the synthetic synthesis of active CHM ingredients, it is essential to critically assess the methodologies employed. Traditional extraction methods, though time-tested, often suffer from low yields and limited scalability. In contrast, biotechnological approaches promise higher efficiency and sustainability but require significant investment in research and development. The scalability of engineered pathways from laboratory conditions to industrial production remains a hurdle, as does the need for cost-effective and robust bioprocessing technologies.

Future research should prioritize uncovering additional biosynthetic pathways of Chinese herbal active ingredients, developing more efficient detection techniques, and enhancing computational methods for pathway prediction and optimization.

Furthermore, optimizing synthetic strategies to improve the stability and yield of engineered pathways is crucial. Addressing these technical challenges will not only support sustainable agriculture and pharmaceutical research but also contribute significantly to human well-being by providing reliable and effective CHM-based therapies.

In conclusion, while the advancements in biotechnological applications for CHM are promising, a balanced approach that critically evaluates methodologies, acknowledges inherent limitations, and addresses potential risks is imperative. By comprehensively understanding and optimizing biosynthetic pathways and regulatory mechanisms, and by leveraging new technologies judiciously, the full potential of CHM can be harnessed to benefit global health sustainably.

CONCLUSIONS

The large-scale biotechnological production of Chinese herbal medicines (CHM) presents significant regulatory and ethical challenges that must be addressed to ensure sustainable and responsible implementation. Variations in regulatory frameworks across regions necessitate harmonization to facilitate international collaboration and market access. Ensuring consistent quality and efficacy requires stringent quality control measures and standardized protocols. Comprehensive safety and efficacy assessments, including clinical trials, are essential to validate biotechnologically produced CHM.

Ethical issues related to intellectual property and bioprospecting must be managed to protect traditional knowledge and ensure fair benefit distribution, preventing biopiracy and promoting equitable access to genetic resources. Additionally, the environmental impact of large-scale production and the socioeconomic effects on communities involved in CHM cultivation must be carefully considered to maintain biodiversity and support local livelihoods. Ethical considerations in genetic engineering, such as maintaining ecosystem balance and addressing the long-term effects of modified traits, are also critical.

Addressing these challenges through interdisciplinary collaborations, the development of comprehensive guidelines, and promoting transparency and stakeholder engagement will support the responsible and ethical advancement of biotechnological innovations in CHM.

ACKNOWLEDGEMENTS

The authors deeply appreciate the anonymous reviewers for their incisive comments, which have significantly enriched the substance and presentation of this literature review. Furthermore, the utilization of pivotal tools such as EndNote for citation management; PubMed, Google Scholar, and Web of Science for comprehensive research access; and Grammarly Editor for expert writing guidance has been instrumental in crafting a meticulous and thorough review, thereby advancing the scholarly conversation in our field.

ADDITIONAL INFORMATION AND DECLARATIONS

Funding

This research received financial support from the National Natural Science Foundation of China (32260089), the Industry-University Collaborative Education Project of Ministry of Education (230901414190927), the Future Outstanding Teachers Training Program of Zunyi Medical University (XJ2023-JX-01-06), the Postgraduate Teaching Reform Project of Zunyi Medical University (ZYK105) and the Undergraduate Education and Teaching Reform Project of Zunyi Medical University (XJJG2022-22; XJKCSZ2023-9, XJJG2024-09). The Science and Technology Department Foundation of Guizhou Province (Contracts No. QKHJC-ZK[2025]MS371, QKPTRC [2019]-027, QKHJC-ZK-2022-623) and the first batch of Class Advisor Studios at Zunyi Medical University (2024BZR-01) supported the APC of this article. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Grant Disclosures

The following grant information was disclosed by the authors:

National Natural Science Foundation of China: 32260089.

Industry-University Collaborative Education Project of Ministry of Education: 230901414190927.

Future Outstanding Teachers Training Program of Zunyi Medical University: XJ2023-JX-01-06.

Postgraduate Teaching Reform Project of Zunyi Medical University: ZYK105.

Undergraduate Education and Teaching Reform Project of Zunyi Medical University: XJJG2022-22, XJKCSZ2023-9, XJJG2024-09.

Science and Technology Department Foundation of Guizhou Province: QKHJC-ZK[2025] MS371, QKPTRC [2019]-027, QKHJC-ZK-2022-623.

Class Advisor Studios at Zunyi Medical University: 2024BZR-01.

Competing Interests

The authors declare that they have no competing interests.

Author Contributions

- Ziyi Guo performed the experiments, analyzed the data, prepared figures and/or tables, and approved the final draft.
- Ning Yang analyzed the data, prepared figures and/or tables, authored or reviewed drafts of the article, and approved the final draft.
- Delin Xu conceived and designed the experiments, authored or reviewed drafts of the article, and approved the final draft.

Data Availability

The following information was supplied regarding data availability:

This is a literature review.

Supplemental Information

Supplemental information for this article can be found online at <http://dx.doi.org/10.7717/peerj.18914#supplemental-information>.

REFERENCES

- Birat K, Binsuwaidean R, Siddiqi TO, Mir SR, Alshammary N, Adnan M, Nazir R, Ejaz B, Malik MQ, Dewangan RP, Ashraf SA, Panda BP. 2022. Report on vincristine-producing endophytic fungus *Nigrospora zimmermanii* from leaves of *Catharanthus roseus*. *Metabolites* **12**(11):1119 DOI [10.3390/metabo12111119](https://doi.org/10.3390/metabo12111119).
- Chang L, Li J, Huang S. 2018. A review of active ingredients from *Cannabis sativa* L. and their medicinal potential. *Chemistry of Life* **38**(2):273–280 DOI [10.13488/j.smhx.20180215](https://doi.org/10.13488/j.smhx.20180215).
- Chao EK, Su XY, Chen SL, Liu JR, Song ZH, Sheng W, Wang CX. 2019. Study on cell factory synthesis of active components from medicinal plants. *Modern Chinese Medicine* **21**:1464–1474 DOI [10.13313/j.issn.1673-4890.20190903009](https://doi.org/10.13313/j.issn.1673-4890.20190903009).
- Chen Y, Su D, Li J, Ying S, Deng H, He X, Zhu Y, Li Y, Chen Y, Pirrello J, Bouzayen M, Liu Y, Liu M. 2020. Overexpression of bHLH95, a basic helix-loop-helix transcription factor family member, impacts trichome formation via regulating gibberellin biosynthesis in tomato. *Journal of Experimental Botany* **71**(12):3450–3462 DOI [10.1093/jxb/eraa114](https://doi.org/10.1093/jxb/eraa114).
- Chen SL, Wu WG, Wang CX, Xiang L, Shi YH, Zhang D, Hu HY. 2019. Molecular genetics research of medicinal plants. *China Journal of Chinese Materia Medica* **44**(12):2421–2432 DOI [10.19540/j.cnki.cjcm.20190514.102](https://doi.org/10.19540/j.cnki.cjcm.20190514.102).
- Chen K, Zhang M, Gao BH, Hasan A, Li JH, Bao Y, Fan JJ, Yu R, Yi Y, Ågren H, Wang Z, Liu H, Ye M, Qiao X. 2023. Characterization and protein engineering of glycosyltransferases for the biosynthesis of diverse hepatoprotective cycloartane-type saponins in *Astragalus membranaceus*. *Plant Biotechnology Journal* **21**(4):698–710 DOI [10.1111/pbi.13983](https://doi.org/10.1111/pbi.13983).
- Cheng L. 2021. Application of new supercritical extraction technology in extraction and separation of effective components of traditional Chinese medicine. *MATEC Web of Conferences* **353**(35):1008 DOI [10.1051/matecconf/202135301008](https://doi.org/10.1051/matecconf/202135301008).
- Chiş A, Noubissi PA, Pop OL, Mureşan CI, Fokam TMA, Kamgang R, Fodor A, Sitar-Tăut AV, Cozma A, Orăsan OH, Hegheş SC, Vulturar R, Suharoschi R. 2023. Bioactive compounds in *Moringa oleifera*: mechanisms of action, focus on their anti-inflammatory properties. *Plants (Basel)* **13**(1):20 DOI [10.3390/plants13010020](https://doi.org/10.3390/plants13010020).
- Daley SK, Cordell GA. 2021. Alkaloids in contemporary drug discovery to meet global disease needs. *Molecules (Basel, Switzerland)* **26**(13):3800 DOI [10.3390/molecules26133800](https://doi.org/10.3390/molecules26133800).
- Dawson RA, Rix GD, Crombie AT, Murrell JC. 2022. Omics-guided prediction of the pathway for metabolism of isoprene by *Variovorax* sp. WS11. *Environmental Microbiology* **24**(11):5151–5164 DOI [10.1111/1462-2920.16149](https://doi.org/10.1111/1462-2920.16149).
- Delfin JC, Watanabe M, Tohge T. 2019. Understanding the function and regulation of plant secondary metabolism through metabolomics approaches. *Theoretical and Experimental Plant Physiology* **31**(1):127–138 DOI [10.1007/s40626-018-0126-1](https://doi.org/10.1007/s40626-018-0126-1).
- Deng CP, Shi M, Fu R, Zhang Y, Wang Q, Zhou Y, Wang Y, Ma XY, Kai GY. 2020. ABA-responsive transcription factor bZIP1 is involved in modulating biosynthesis of phenolic acids and tanshinones in *Salvia miltiorrhiza*. *Journal of Experimental Botany* **71**(19):5948–5962 DOI [10.1093/jxb/eraa295](https://doi.org/10.1093/jxb/eraa295).

- Ding ML, Zhang B, Zhang S, Hao RR, Xia Y, Ma PD, Dong J.** 2023. The SmNPR4-SmTGA5 module regulates SA-mediated phenolic acid biosynthesis in *Salvia miltiorrhiza* hairy roots. *Horticulture Research* 10(5):uhad066 DOI 10.1093/hr/uhad066.
- Doan TN, Le TD, Ho NA, Ho TT, Do TT, Hoang H, Nguyen MH, Bui TM, Chu HH.** 2024. Isolation, anticancer potency, and camptothecin-producing ability of endophytic fungi isolated from *Ixora chinensis*. *Science Progress* 107(2):368504241253675 DOI 10.1177/00368504241253675.
- Du Y, Ma H, Liu Y, Gong R, Lan Y, Zhao J, Liu G, Lu Y, Wang S, Jia H, Li N, Zhang R, Wang J, Sun G.** 2024. Major quality regulation network of flavonoid synthesis governing the bioactivity of black wolfberry. *New Phytologist* 242(2):558–575 DOI 10.1111/nph.19602.
- Englund E, Shabestary K, Hudson EP, Lindberg P.** 2018. Systematic overexpression study to find target enzymes enhancing production of terpenes in *Synechocystis PCC 6803*, using isoprene as a model compound. *Metabolic Engineering* 49:164–177 DOI 10.1016/j.ymben.2018.07.004.
- Gao K.** 2015. Advances in studies on transcriptional factor regulation of biosynthesis of active components in medicinal plants. *Chinese Traditional and Herbal Drugs* 46(20):3100–3108 DOI 10.7501/j.issn.0253-2670.2015.20.024.
- Gao K, Zha WL, Zhu JX, Zheng C, Zi JC.** 2021. A review: biosynthesis of plant-derived labdane-related diterpenoids. *Chinese Journal of Natural Medicines* 19(9):666–674 DOI 10.1016/S1875-5364(21)60100-0.
- Goyal P, Devi R, Verma B, Hussain S, Arora P, Tabassum R, Gupta S.** 2023. WRKY transcription factors: evolution, regulation, and functional diversity in plants. *Protoplasma* 260(2):331–348 DOI 10.1007/s00709-022-01794-7.
- Guo M, Lv H, Chen H, Dong S, Zhang J, Liu W, He L, Ma Y, Yu H, Chen S, Luo H.** 2023. Strategies on biosynthesis and production of bioactive compounds in medicinal plants. *Chinese Herbal Medicines* 16(1):13–26 DOI 10.1016/j.chmed.2023.01.007.
- Guo L, Yao H, Chen W, Wang X, Ye P, Xu Z, Zhang S, Wu H.** 2022. Natural products of medicinal plants: biosynthesis and bioengineering in post-genomic era. *Horticulture Research* 9:uhac223 DOI 10.1093/hr/uhac223.
- Han J, Li S.** 2023. De novo biosynthesis of berberine and halogenated benzylisoquinoline alkaloids in *Saccharomyces cerevisiae*. *Communications Chemistry* 6(1):27 DOI 10.1038/s42004-023-00821-9.
- He XY, Chen YW, Xia YT, Hong XY, You HQ, Zhang R, Liang ZS, Cui Q, Zhang SC, Zhou M, Yang D.** 2024. DNA methylation regulates biosynthesis of tanshinones and phenolic acids during growth of *Salvia miltiorrhiza*. *Plant Physiology* 194(4):2086–2100 DOI 10.1093/plphys/kiad573.
- Hridoy M, Gorapi MZH, Noor S, Chowdhury NS, Rahman MM, Muscari I, Masia F, Adorisio S, Delfino DV, Mazid MA.** 2022. Putative anticancer compounds from plant-derived endophytic fungi: a review. *Molecules* 27(1):296 DOI 10.3390/molecules27010296.
- Hu YJ, Cheng H, Zhang Y, Zhang J, Niu SQ, Wang XS, Li WJ, Zhang J, Yao YC.** 2021. The MdMYB16/MdMYB1-miR7125-MdCCR module regulates the homeostasis between anthocyanin and lignin biosynthesis during light induction in apple. *The New Phytologist* 231(3):1105–1122 DOI 10.1111/nph.17431.
- Hu B, Zhao X, Wang E, Zhou J, Li J, Chen J, Du G.** 2023. Efficient heterologous expression of cytochrome P450 enzymes in microorganisms for the biosynthesis of natural products. *Critical Reviews in Biotechnology* 43(2):227–241 DOI 10.1080/07388551.2022.2029344.
- Huang R, Liu L, He X, Wang W, Hou Y, Chen J, Li Y, Zhou H, Tian T, Wang W, Xu Q, Yu Y, Zhou T.** 2021. Isolation and functional characterization of multiple NADPH-cytochrome P450

reductase genes from *Camellia sinensis* in view of catechin biosynthesis. *Journal of Agricultural and Food Chemistry* **69**(49):14926–14937 DOI [10.1021/acs.jafc.1c04255](https://doi.org/10.1021/acs.jafc.1c04255).

Huang XR, Zhang WW, Liao YL, Ye JB, Xu F. 2023. Contemporary understanding of transcription factor regulation of terpenoid biosynthesis in plants. *Planta* **259**(1):2 DOI [10.1007/s00425-023-04268-z](https://doi.org/10.1007/s00425-023-04268-z).

Islam M, Malakar S, Rao MV, Kumar N, Sahu JK. 2023. Recent advancement in ultrasound-assisted novel technologies for the extraction of bioactive compounds from herbal plants: a review. *Food Science and Biotechnology* **32**(13):1763–1782 DOI [10.1007/s10068-023-01346-6](https://doi.org/10.1007/s10068-023-01346-6).

Jain S, Tripathi S, Tripathi PK. 2023. Antioxidant and antiarthritic potential of berberine: in vitro and in vivo studies. *Chinese Herbal Medicines* **15**(4):549–555 DOI [10.1016/j.chmed.2023.02.007](https://doi.org/10.1016/j.chmed.2023.02.007).

Javan SL, Kashkooli AB, Shojaeiyan A, Majidian S. 2024. Transcriptomic data reveals the dynamics of terpenoids biosynthetic pathway of fenugreek. *BMC Genomics* **25**(1):390 DOI [10.1186/s12864-024-10253-x](https://doi.org/10.1186/s12864-024-10253-x).

Javed T, Gao SJ. 2023. WRKY transcription factors in plant defense. *Trends in Genetics* **39**(10):787–801 DOI [10.1016/j.tig.2023.07.001](https://doi.org/10.1016/j.tig.2023.07.001).

Ji X, Li Z, Zhang M, Lang S, Song X. 2024. ChMYB1-ChbHLH42-ChTTG1 module regulates abscisic acid-induced anthocyanin biosynthesis in *Cerasus humilis*. *Horticultural Plant Journal* **10**(1):51–65 DOI [10.1016/j.hpj.2023.05.015](https://doi.org/10.1016/j.hpj.2023.05.015).

Jiang B, Gao L, Wang H, Sun Y, Zhang X, Ke H, Liu S, Ma P, Liao Q, Wang Y, Wang H, Liu Y, Du R, Rogge T, Li W, Shang Y, Houk KN, Xiong X, Xie D, Huang S, Lei X, Yan J. 2024a. Characterization and heterologous reconstitution of Taxus biosynthetic enzymes leading to baccatin III. *Science* **383**(6683):622–629 DOI [10.1126/science.adj3484](https://doi.org/10.1126/science.adj3484).

Jiang T, Zhang Y, Zuo GG, Luo T, Wang H, Zhang R, Luo ZY. 2024b. Transcription factor PgNAC72 activates DAMMARENEDIOL SYNTHASE expression to promote ginseng saponin biosynthesis. *Plant Physiology* **195**(4):2952–2969 DOI [10.1093/plphys/kiae202](https://doi.org/10.1093/plphys/kiae202).

Jin JQ, Qu FR, Huang H, Liu QS, Wei MY, Zhou Y, Huang KL, Cui Z, Chen JD, Dai WD, Zhu L, Yao MZ, Zhang ZM, Chen L. 2023. Characterization of two O-methyltransferases involved in the biosynthesis of O-methylated catechins in tea plant. *Nature Communications* **14**(1):5075 DOI [10.1038/s41467-023-40868-9](https://doi.org/10.1038/s41467-023-40868-9).

Khoso MA, Wang M, Zhou Z, Huang Y, Li S, Zhang Y, Qian G, Ko SN, Pang Q, Liu C, Li L. 2024. *Bacillus altitudinis* AD13-4 enhances saline-alkali stress tolerance of alfalfa and affects composition of rhizosphere soil microbial community. *International Journal of Molecular Sciences* **25**(11):5785 DOI [10.3390/ijms25115785](https://doi.org/10.3390/ijms25115785).

Kishimoto S, Sato M, Tsunematsu Y, Watanabe K. 2016. Evaluation of biosynthetic pathway and engineered biosynthesis of alkaloids. *Molecules (Basel, Switzerland)* **21**(8):1078 DOI [10.3390/molecules21081078](https://doi.org/10.3390/molecules21081078).

Kuang XJ, Wang CX, Zou LQ, Li Y, Sun C. 2016. Recent advances in biosynthetic pathway and synthetic biology of taxol. *Zhongguo Zhongyao Zazhi* **41**(22):4144–4149 DOI [10.4268/cjcm20162210](https://doi.org/10.4268/cjcm20162210).

Kundu P, Vadassery J. 2021. Role of WRKY transcription factors in plant defense against lepidopteran insect herbivores: an overview. *Journal of Plant Biochemistry and Biotechnology* **30**(4):698–707 DOI [10.1007/s13562-021-00730-9](https://doi.org/10.1007/s13562-021-00730-9).

LaFountain AM, Yuan YW. 2021. Repressors of anthocyanin biosynthesis. *The New Phytologist* **231**(3):933–949 DOI [10.1111/nph.17397](https://doi.org/10.1111/nph.17397).

- Li G, Chen D.** 2024. Comparison of different extraction methods of active ingredients of Chinese medicine and natural products. *Journal of Separation Science* **47**(1):2300712 DOI [10.1002/jssc.202300712](https://doi.org/10.1002/jssc.202300712).
- Li SH, Dong YX, Li DL, Shi SL, Zhao N, Liao JL, Liu Y, Chen HY.** 2024a. Eggplant transcription factor SmMYB5 integrates jasmonate and light signaling during anthocyanin biosynthesis. *Plant Physiology* **194**(2):1139–1165 DOI [10.1093/plphys/kiad531](https://doi.org/10.1093/plphys/kiad531).
- Li H, Guo Z, Xu M, Zhao J, Xu D.** 2024b. Molecular mechanism of miRNA mediated biosynthesis of secondary metabolites in medicinal plants. *Plant Physiology and Biochemistry* **208**(3):108524 DOI [10.1016/j.plaphy.2024.108524](https://doi.org/10.1016/j.plaphy.2024.108524).
- Li MK, Ma MY, Wu ZK, Liang XQ, Zheng QS, Li DF, An TY, Wang GL.** 2023a. Advances in the biosynthesis and metabolic engineering of rare ginsenosides. *Applied Microbiology and Biotechnology* **107**(11):3391–3404 DOI [10.1007/s00253-023-12549-6](https://doi.org/10.1007/s00253-023-12549-6).
- Li M, Ng M, Ng LG.** 2023. Firing up neutrophil anti-tumor immunity with cocktails. *Cancer Cell* **41**(2):227–229 DOI [10.1016/j.ccr.2023.01.005](https://doi.org/10.1016/j.ccr.2023.01.005).
- Li XQ, Song YN, Wang SJ, Rahman K, Zhu JY, Zhang H.** 2018. Saikosaponins: a review of pharmacological effects. *Journal of Asian Natural Products Research* **20**(5):399–411 DOI [10.1080/10286020.2018.1465937](https://doi.org/10.1080/10286020.2018.1465937).
- Li YL, Wang J, Li LY, Song WH, Li M, Hua X, Wang Y, Yuan JF, Xue ZY.** 2023b. Natural products of pentacyclic triterpenoids: from discovery to heterologous biosynthesis. *Natural Product Reports* **40**(8):1303–1353 DOI [10.1039/D2NP00063F](https://doi.org/10.1039/D2NP00063F).
- Li Y, Wu H.** 2018. The research progress of the correlation between growth development and dynamic accumulation of the effective components in medicinal plants. *Chinese Bulletin of Botany* **53**(3):293–304 DOI [10.11983/CBB18081](https://doi.org/10.11983/CBB18081).
- Li S, Xia L.** 2020. Precise gene replacement in plants through CRISPR/Cas genome editing technology: current status and future perspectives. *aBIOTECH* **1**(1):58–73 DOI [10.1007/s42994-019-00009-7](https://doi.org/10.1007/s42994-019-00009-7).
- Liang X, Rui-Bing C, Yu WU, Lei Z.** 2020. Research progress on effect of AP2/ERF transcription factors in regulating secondary metabolite biosynthesis. *China Journal of Chinese Materia Medica* **45**(22):5412–5420 DOI [10.7501/j.issn.0253-2670.2016.09.027](https://doi.org/10.7501/j.issn.0253-2670.2016.09.027).
- Liao BS, Shen XF, Xiang L, Guo S, Chen SY, Meng Y, Liang Y, Ding DD, Bai JQ, Zhang D, Czechowski T, Li Y, Yao H, Ma T, Howard C, Sun C, Liu H, Liu J, Pei J, Gao J, Wang J, Qiu X, Huang Z, Li H, Yuan L, Wei J, Graham I, Xu J, Zhang B, Chen S.** 2022. Allele-aware chromosome-level genome assembly of Artemisia annua reveals the correlation between ADS expansion and artemisinin yield. *Molecular Plant* **15**(8):1310–1328 DOI [10.1016/j.molp.2022.05.013](https://doi.org/10.1016/j.molp.2022.05.013).
- Lin CC, Chen DW, Dai JG.** 2022. Advances of synthetic biology of flavonoids. *Acta Pharmaceutica Sinica* **57**(5):1322–1335 DOI [10.16438/j.0513-4870.2022-0008](https://doi.org/10.16438/j.0513-4870.2022-0008).
- Liu SC, Gao XK, Shi M, Sun MH, Li KL, Cai Y, Chen C, Wang C, Maoz I, Guo XH, Kai G.** 2023. Jasmonic acid regulates the biosynthesis of medicinal metabolites via the JAZ9-MYB76 complex in Salvia miltiorrhiza. *Horticulture Research* **10**(3):uhad004 DOI [10.1093/hr/uhad004](https://doi.org/10.1093/hr/uhad004).
- Liu T, Luo T, Guo XQ, Zou X, Zhou DH, Afrin S, Li G, Zhang Y, Zhang R, Luo ZY.** 2019a. PgMYB2, a MeJA-responsive transcription factor, positively regulates the dammarenediol synthase gene expression in Panax Ginseng. *International Journal of Molecular* **20**(9):2219 DOI [10.3390/ijms20092219](https://doi.org/10.3390/ijms20092219).
- Liu M, Shi Z, Zhang X, Wang M, Zhang L, Zheng K, Liu J, Hu X, Di C, Qian Q, He Z, Yang DL.** 2019b. Inducible overexpression of ideal plant architecture1 improves both yield and disease resistance in rice. *Nature Plants* **5**(4):389–400 DOI [10.1038/s41477-019-0383-2](https://doi.org/10.1038/s41477-019-0383-2).

- Liu Y, Wang Y, Guo F, Zhan L, Mohr T, Cheng P, Huo N, Gu R, Pei D, Sun J, Tang L, Long C, Huang L, Gu YQ.** 2017. Deep sequencing and transcriptome analyses to identify genes involved in secoiridoid biosynthesis in the Tibetan medicinal plant *Swertia mussotii*. *Scientific Reports* 7(1):43108 DOI 10.1038/srep43108.
- Liu T, Zhang W, Wang S, Tian Y, Wang Y, Gao R, Chen S, Sun W, Ma W, Xu Z.** 2024. Metabolome and transcriptome association study reveals biosynthesis of specialized benzylisoquinoline alkaloids in *Phellodendron amurense*. *Chinese Herbal Medicines* DOI 10.1016/j.chmed.2024.11.003.
- Lu S.** 2021. Biosynthesis and regulatory mechanisms of bioactive compounds in *Salvia miltiorrhiza*, a model system for medicinal plant biology. *Critical Reviews in Plant Sciences* 40(3):243–283 DOI 10.1080/07352689.2021.1935719.
- Lu Y, Jiang JG.** 2013. Application of enzymatic method in the extraction and transformation of natural botanical active ingredients. *Applied Biochemistry and Biotechnology* 169(3):923–940 DOI 10.1007/s12010-012-0026-9.
- Lu ZM, Zhang RT, Huang XB, Cao XT, Shen XY, Fan L, Hou CL.** 2024. Optimisation of hypocrellin production in Shiraia-like fungi via genetic modification involving a transcription factor gene and a putative monooxygenase gene. *Mycology: An International Journal on Fungal Biology* 15(2):272–281 DOI 10.1080/21501203.2023.2295406.
- Lv HZ, Liu WJ, He L.** 2017. Advances on the study of gene clusters involved in plant secondary metabolism. *Plant Science Journal* 35(4):609–621 DOI 10.11913/PSJ.2095-0837.2017.40609.
- Ma Y, Cai Y, Ma XJ, Cui GH, Tang JF, Zeng W, Zhang SH, Guo J, Huang LQ.** 2020. Research progress of P450 in the biosynthesis of bioactive compound of medicinal plants. *Yaoxue Xuebao* 55:1573–1589 DOI 10.16438/j.0513-4870.2020-0035.
- Ma ZZ, Pang XQ, Sheng R, Pei XL, Wang QY, Yin XP.** 2015. Research advances of key enzymes in the biosynthes is pathways of isoprenoids. *Journal of Hangzhou Normal University (Natural Science Edition)* 14(6):608–615 DOI 10.3969/j.issn.1674-232X.2015.06.010.
- Mahiwal S, Pahuja S, Pandey GK.** 2024. Review: structural-functional relationship of WRKY transcription factors: unfolding the role of WRKY in plants. *International Journal of Biological Macromolecules* 257(Pt 2):128769 DOI 10.1016/j.ijbiomac.2023.128769.
- Miao HY, Xia CC, Yu SH, Wang JS, Zhao YT, Wang QM.** 2023. Enhancing health-promoting isothiocyanates in Chinese kale sprouts via manipulating BoESP. *Horticulture Research* 10(4):uhad029 DOI 10.1093/hr/uhad029.
- Narayananakutty A, Famurewa AC, Oprea E.** 2024. Natural bioactive compounds and human health. *Molecules (Basel, Switzerland)* 29(14):3372 DOI 10.3390/molecules29143372.
- Paddon CJ, Westfall PJ, Pitera DJ, Benjamin K, Fisher K, McPhee D, Leavell MD, Tai A, Main A, Eng D, Polichuk DR, Teoh KH, Reed DW, Treynor T, Lenihan J, Fleck M, Bajad S, Dang G, Dengrove D, Diola D, Dorin G, Ellens KW, Fickes S, Galazzo J, Gaucher SP, Geistlinger T, Henry R, Hepp M, Horning T, Iqbal T, Jiang H, Kizer L, Lieu B, Melis D, Moss N, Regentin R, Secrest S, Tsuruta H, Vazquez R, Westblade LF, Xu L, Yu M, Zhang Y, Zhao L, Lievense J, Covello PS, Keasling JD, Reiling KK, Renninger NS, Newman JD.** 2013. High-level semi-synthetic production of the potent antimalarial artemisinin. *Nature* 496(7446):528–532 DOI 10.1038/nature12051.
- Perez-Matas E, Hidalgo-Martinez D, Moyano E, Palazon J, Bonfill M.** 2024. Overexpression of BAPT and DBTNBT genes in *Taxus baccata* in vitro cultures to enhance the biotechnological production of paclitaxel. *Plant Biotechnology Journal* 22(1):233–247 DOI 10.1111/pbi.14182.

- Qiu X, Zhang Y, Luo Y, Zhang Y.** 2024. SmCYP71D373 of *Salvia miltiorrhiza* catalyzes the methyl oxidation reaction of tanshinone IIA-19 position. *Industrial Crops and Products* **212(1)**:118323 DOI [10.1016/j.indcrop.2024.118323](https://doi.org/10.1016/j.indcrop.2024.118323).
- Qu Y, Safanova O, De Luca V.** 2019. Completion of the canonical pathway for assembly of anticancer drugs vincristine/vinblastine in *Catharanthus roseus*. *The Plant Journal: For Cell and Molecular Biology* **97(2)**:257–266 DOI [10.1111/tpj.14111](https://doi.org/10.1111/tpj.14111).
- Rashid A, Khajuria M, Ali V, Faiz S, Jamwal S, Vyas D.** 2023. Genome-wide identification and expression profiling of WRKY family suggest their potential role in cannabinoid regulation in *Cannabis sativa* L. *Industrial Crops and Products* **206(W1)**:117706 DOI [10.1016/j.indcrop.2023.117706](https://doi.org/10.1016/j.indcrop.2023.117706).
- Ren CX, Xi ZQ, Xian B, Chen C, Huang XL, Jiang HJ, Chen J, Peng C, Pei J.** 2023. Identification and characterization of CtUGT3 as the key player of astragalin biosynthesis in *Carthamus tinctorius* L. *Journal of Agricultural and Food Chemistry* **71(43)**:16221–16232 DOI [10.1021/acs.jafc.3c05117](https://doi.org/10.1021/acs.jafc.3c05117).
- Rhee HJ, Kim EJ, Lee JK.** 2007. Physiological polyamines: simple primordial stress molecules. *Journal of Cellular and Molecular Medicine* **11(4)**:685–703 DOI [10.1111/j.1582-4934.2007.00077.x](https://doi.org/10.1111/j.1582-4934.2007.00077.x).
- Sahu A, Mostafa MG, Weraduwage SM, Sharkey TD.** 2023. Hydroxymethylbutenyl diphosphate accumulation reveals MEP pathway regulation for high CO(2)-induced suppression of isoprene emission. *Proceedings of the National Academy of Sciences of the United States of America* **120(41)**:e2309536120 DOI [10.1073/pnas.2309536120](https://doi.org/10.1073/pnas.2309536120).
- Schafhauser T, Jahn L, Kirchner N, Kulik A, Flor L, Lang A, Caradec T, Fewer DP, Sivonen K, van Berkel WJH, Jacques P, Weber T, Gross H, van Pee KH, Wohlleben W, Ludwig-Müller J.** 2019. Antitumor astins originate from the fungal endophyte *Cyanodermella asteris* living within the medicinal plant *Aster tataricus*. *Proceedings of the National Academy of Sciences of the United States of America* **116(52)**:26909–26917 DOI [10.1073/pnas.1910527116](https://doi.org/10.1073/pnas.1910527116).
- Shi M, Liao P, Nile SH, Georgiev MI, Kai G.** 2021. Biotechnological exploration of transformed root culture for value-added products. *Trends in Biotechnology* **39(2)**:137–149 DOI [10.1016/j.tibtech.2020.06.012](https://doi.org/10.1016/j.tibtech.2020.06.012).
- Subban K, Kempken F.** 2023. Insights into Taxol biosynthesis by endophytic fungi. *Applied Microbiology and Biotechnology* **107(20)**:6151–6162 DOI [10.1007/s00253-023-12713-y](https://doi.org/10.1007/s00253-023-12713-y).
- Sun W, Yin Q, Wan H, Gao R, Xiong C, Xie C, Meng X, Mi Y, Wang X, Wang C, Chen W, Xie Z, Xue Z, Yao H, Sun P, Xie X, Hu Z, Nelson DR, Xu Z, Sun X, Chen S.** 2023. Characterization of the horse chestnut genome reveals the evolution of aescin and aesculin biosynthesis. *Nature Communications* **14(1)**:6470 DOI [10.1038/s41467-023-42253-y](https://doi.org/10.1038/s41467-023-42253-y).
- Tiwari P, Bae H.** 2022. Endophytic fungi: key insights, emerging prospects, and challenges in natural product drug discovery. *Microorganisms* **10(2)**:360 DOI [10.3390/microorganisms10020360](https://doi.org/10.3390/microorganisms10020360).
- Unuofin JO, Lebelo SL.** 2020. Antioxidant effects and mechanisms of medicinal plants and their bioactive compounds for the prevention and treatment of type 2 diabetes: an updated review. *Oxidative Medicine and Cellular Longevity* **2020(1)**:1356893 DOI [10.1155/2020/1356893](https://doi.org/10.1155/2020/1356893).
- Upadhyay S, Jeena GS, Shikha, Shukla RK.** 2018. Recent advances in steroidal saponins biosynthesis and in vitro production. *Planta* **248(3)**:519–544 DOI [10.1007/s00425-018-2911-0](https://doi.org/10.1007/s00425-018-2911-0).
- Venugopalan A, Srivastava S.** 2015. Endophytes as in vitro production platforms of high value plant secondary metabolites. *Biotechnology Advances* **33(6)**:873–887 DOI [10.1016/j.biotechadv.2015.07.004](https://doi.org/10.1016/j.biotechadv.2015.07.004).

- Wang X, Li CF, Zhou C, Li J, Zhang YS.** 2017. Molecular characterization of the C-glucosylation for puerarin biosynthesis in Pueraria lobata. *The Plant Journal: For Cell and Molecular Biology* **90**(3):535–546 DOI [10.1111/tpj.13510](https://doi.org/10.1111/tpj.13510).
- Wang SY, Wu GQ, Wei M.** 2024. Functional mechanisms of WRKY transcription factors in regulating plant response to abiotic stresses. *Chinese Journal of Biotechnology* **40**(1):35–52 DOI [10.13345/j.cjb.230298](https://doi.org/10.13345/j.cjb.230298).
- Wani SH, Anand S, Singh B, Bohra A, Joshi R.** 2021. WRKY transcription factors and plant defense responses: latest discoveries and future prospects. *Plant Cell Reports* **40**(7):1071–1085 DOI [10.1007/s00299-021-02691-8](https://doi.org/10.1007/s00299-021-02691-8).
- Wei W, Guo T, Fan W, Ji M, Fu Y, Lian C, Chen S, Ma W, Ma W, Feng S.** 2024. Integrative analysis of metabolome and transcriptome provides new insights into functional components of Lili Bulbus. *Chinese Herbal Medicines* **16**(3):435–448 DOI [10.1016/j.chmed.2023.10.004](https://doi.org/10.1016/j.chmed.2023.10.004).
- Wicks C, Hudlicky T, Rinner U.** 2021. Morphine alkaloids: history, biology, and synthesis. *The Alkaloids Chemistry and Biology* **86**:145–342 DOI [10.1016/bs.alkal.2021.04.001](https://doi.org/10.1016/bs.alkal.2021.04.001).
- Wu J, Liang JL, Lin RM, Cai X, Zhang L, Guo XL, Wang TP, Chen HX, Wang XW.** 2022. Investigation of Brassica and its relative genomes in the post-genomics era. *Horticulture Research* **9**:uhac182 DOI [10.1093/hr/uhac182](https://doi.org/10.1093/hr/uhac182).
- Xia J, Lou GG, Zhang L, Huang YB, Yang J, Guo J, Qi ZC, Li ZH, Zhang GL, Xu SC, Song X, Zhang X, Wei Y, Liang Z, Yang D.** 2023. Unveiling the spatial distribution and molecular mechanisms of terpenoid biosynthesis in Salvia miltiorrhiza and S. grandifolia using multi-omics and DESI-MSI. *Horticulture Research* **10**(7):uhad109 DOI [10.1093/hr/uhad109](https://doi.org/10.1093/hr/uhad109).
- Xu YY, Chen Z, Jia LM, Weng X.** 2021a. Advances in understanding of the biosynthetic pathway and regulatory mechanism of triterpenoid saponins in plants. *Scientia Sinica Vitae* **51**(5):525–555 DOI [10.1360/SSV-2020-0230](https://doi.org/10.1360/SSV-2020-0230).
- Xu H, Zhang Y, Wang P, Zhang J, Chen H, Zhang L, Du X, Zhao C, Wu D, Liu C.** 2021b. A comprehensive review of integrative pharmacology-based investigation: a paradigm shift in traditional Chinese medicine. *Acta Pharmaceutica Sinica B* **11**(6):1379–1399 DOI [10.1016/j.apsb.2021.03.024](https://doi.org/10.1016/j.apsb.2021.03.024).
- Yang H, Drugs H.** 2017. Research progress on triterpenoid saponins in Panax ginseng and its ecological effects. *Chinese Traditional and Herbal Drugs* **48**(8):1692–1698 DOI [10.7501/j.issn.0253-2670.2017.08.033](https://doi.org/10.7501/j.issn.0253-2670.2017.08.033).
- Yang ZJ, Li XB, Yang L, Peng SF, Song WL, Lin Y, Xiang GS, Li Y, Ye S, Ma CH, Miao J, Zhang G, Chen W, Yang S, Dong Y.** 2023a. Comparative genomics reveals the diversification of triterpenoid biosynthesis and origin of ocotillol-type triterpenes in Panax. *Plant Communications* **4**(4):100591 DOI [10.1016/j.xplc.2023.100591](https://doi.org/10.1016/j.xplc.2023.100591).
- Yang ZR, Mao X, Li RZ.** 2005. Research progress in genetic engineering of plant secondary metabolism. *Journal of Plant Physiology and Molecular Biology* **31**(1):11–18 DOI [10.3321/j.issn:1671-3877.2005.01.002](https://doi.org/10.3321/j.issn:1671-3877.2005.01.002).
- Yang R, Shi Q, Huang T, Yan Y, Li S, Fang Y, Li Y, Liu L, Liu L, Wang X, Peng Y, Fan J, Zou L, Lin S, Chen G.** 2023b. The natural pyrazolotriazine pseudoiodinine from Pseudomonas mosselii 923 inhibits plant bacterial and fungal pathogens. *Nature Communications* **14**(1):734 DOI [10.1038/s41467-023-36433-z](https://doi.org/10.1038/s41467-023-36433-z).
- Ye T, An Z, Song M, Wei X, Liu L, Zhang X, Zhang H, Liu H, Fang H.** 2024. Strategies to enhance the hydrolytic activity of Escherichia coli BL21 penicillin G acylase based on heterologous expression and targeted mutagenesis. *Colloids and Surfaces B: Biointerfaces* **246**:114356 DOI [10.1016/j.colsurfb.2024.114356](https://doi.org/10.1016/j.colsurfb.2024.114356).

- Yuan MY, Shu GP, Zhou JH, He P, Xiang LE, Yang CX, Chen M, Liao ZH, Zhang FY.** 2023. AabHLH113 integrates jasmonic acid and abscisic acid signaling to positively regulate artemisinin biosynthesis in *Artemisia annua*. *The New Phytologist* 237(3):885–899 DOI 10.1111/nph.18567.
- Yuan X, Li R, He W, Xu W, Xu W, Yan G, Xu S, Chen L, Feng Y, Li H.** 2024. Progress in Identification of UDP-Glycosyltransferases for Ginsenoside Biosynthesis. *Journal of Natural Products* 87(4):1246–1267 DOI 10.1021/acs.jnatprod.3c00630.
- Zhan J, Meyers BC.** 2023. Plant Small RNAs: their biogenesis, regulatory roles, and functions. *Annual Review of Plant Biology* 74(1):21–51 DOI 10.1146/annurev-arplant-070122-035226.
- Zhang L, Duan Z, Ma S, Sun S, Sun M, Xiao Y, Ni N, Irfan M, Chen L, Sun Y.** 2023a. SIMYB7, an AtMYB4-Like R2R3-MYB transcription factor, inhibits anthocyanin accumulation in *Solanum lycopersicum* fruits. *Journal of Agricultural and Food Chemistry* 71(48):18758–18768 DOI 10.1021/acs.jafc.3c05185.
- Zhang HY, He Q, Xing LS, Wang RY, Wang Y, Liu Y, Zhou QH, Li XZ, Jia Z, Liu Z, Miao Y, Lin T, Li W, Du H.** 2024a. The haplotype-resolved genome assembly of autotetraploid rhubarb *Rheum officinale* provides insights into its genome evolution and massive accumulation of anthraquinones. *Plant Communications* 5(1):100677 DOI 10.1016/j.xplc.2023.100677.
- Zhang Y, Ju JM, Jiao L, Yang BF.** 2023b. Bioactive components of Chinese herbal Medicines in the treatment of glucose and lipid metabolism disorders: evidence and potential mechanisms. *Engineering* 29(24):73–82 DOI 10.1016/j.eng.2023.03.004.
- Zhang X, Song JY, Hu YL, Xu J, Xu ZC, Ji AJ, Luo HM, Chen SL.** 2014. Research progress of the regulation on active compound biosynthesis by the bHLH transcription factors in plants. *Acta Pharmaceutica Sinica* 49(4):435–442 DOI 10.16438/j.0513-4870.2014.04.007.
- Zhang Y, Zhang J, Yan J, Qi X, Wang Y, Zheng Z, Liang J, Ling J, Chen Y, Tang X, Zeng X, Yu P, Zhang D.** 2024b. Application of fermented Chinese herbal medicines in food and medicine field: from an antioxidant perspective. *Trends in Food Science & Technology* 148(9):104410 DOI 10.1016/j.tifs.2024.104410.
- Zhao Y, Liu GZ, Yang F, Liang YL, Gao QQ, Xiang CF, Li X, Yang R, Zhang GH, Jiang HF, Yu L, Yang S.** 2023a. Multilayered regulation of secondary metabolism in medicinal plants. *Molecular Horticulture* 3(1):11 DOI 10.1186/s43897-023-00059-y.
- Zhao W, Shen C, Zhu J, Ou C, Liu M, Dai W, Liu X, Liu J.** 2020. Identification and characterization of methyltransferases involved in benzylisoquinoline alkaloids biosynthesis from *Stephania intermedia*. *Biotechnology Letters* 42(3):461–469 DOI 10.1007/s10529-019-02785-0.
- Zhao D, Zhang Y, Ren H, Shi Y, Dong D, Li Z, Cui G, Shen Y, Mou Z, Kennelly EJ, Huang L, Ruan J, Chen S, Yu D, Cun Y.** 2023b. Multi-omics analysis reveals the evolutionary origin of diterpenoid alkaloid biosynthesis pathways in *Aconitum*. *Journal of Integrative Plant Biology* 65(10):2320–2335 DOI 10.1111/jipb.13565.
- Zheng H, Fu XQ, Shao J, Tang YL, Yu MY, Li L, Huang LQ, Tang KX.** 2023. Transcriptional regulatory network of high-value active ingredients in medicinal plants. *Trends in Plant Science* 28(4):429–446 DOI 10.1016/j.tplants.2022.12.007.
- Zhong CF, Chen CY, Gao X, Tan CY, Bai H, Ning K.** 2022. Multi-omics profiling reveals comprehensive microbe-plant-metabolite regulation patterns for medicinal plant *Glycyrrhiza uralensis* Fisch. *Plant Biotechnology Journal* 20(10):1874–1887 DOI 10.1111/pbi.13868.
- Zhong CM, Tang Y, Pang B, Li XK, Yang YP, Deng J, Feng CY, Li LF, Ren GP, Wang YQ, Peng J, Sun S, Liang S, Wang X.** 2020. The R2R3-MYB transcription factor GhMYB1a

regulates flavonol and anthocyanin accumulation in *Gerbera hybrida*. *Horticulture Research* 7(1):78 DOI 10.1038/s41438-020-0296-2.

- Zhou Z, Feng JX, Huo JC, Qiu S, Zhang P, Wang Y, Li Q, Li YJ, Han CC, Feng XB, Duan Y, Chen R, Xiao Y, He Y, Zhang L, Chen W.** 2024. Versatile CYP98A enzymes catalyse meta-hydroxylation reveals diversity of salvianolic acids biosynthesis. *Plant Biotechnology Journal* 22(6):1536–1548 DOI 10.1111/pbi.14284.
- Zhou D, Gao S, Wang H, Lei T, Shen J, Gao J, Chen S, Yin J, Liu J.** 2016. De novo sequencing transcriptome of endemic *Gentiana straminea* (Gentianaceae) to identify genes involved in the biosynthesis of active ingredients. *Gene* 575(1):160–170 DOI 10.1016/j.gene.2015.08.055.
- Zhou JJ, Huang DQ, Liu CL, Hu ZL, Li H, Lou SL.** 2023. Research progress in heterologous crocin production. *Marine Drugs* 22(1):22 DOI 10.3390/md22010022.
- Zhou Z, Li Q, Chen WS, Zhang L.** 2021. Research strategies of natural products biosynthesis pathways and key enzymes in medicinal plants. *Biotechnology Bulletin* 37(8):25 DOI 10.13560/j.cnki.biotech.bull.1985.2021-0949.
- Zhou YH, Xu XD, Chen YZ, Gao J, Shi QY, Tian L, Cao L.** 2022. Combined metabolome and transcriptome analyses reveal the flavonoids changes and biosynthesis mechanisms in different organs of *Hibiseu manihot* L. *Frontiers in Plant Science* 13:817378 DOI 10.3389/fpls.2022.817378.
- Zhu L, Yuan C, Liu YF.** 2024. Research progress on plant secondary metabolite biosynthetic gene clusters. *Chinese Bulletin of Botany* 59(1):134 DOI 10.11983/CBB22232.
- Zuo X, Miao CY, Li MM, Gu L, Yang X, Song C, Li MJ, Du JF, Xie CX, Liu XY, Sun H, Li L, Zhang Z, Wang F.** 2023. Purple Rehmannia: investigation of the activation of R2R3-MYB transcription factors involved in anthocyanin biosynthesis. *Physiologia Plantarum* 175(3):e13920 DOI 10.1111/ppl.13920.